ALLIANCE PHARMA PLC

Major Shareholding Notification • Jun 26, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2102J

Alliance Pharma PLC

26 June 2017

For immediate release	26 June 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder.   In accordance with AIM rule 17, the following details are now notified:

(a)  Identity of the significant shareholder: Mr Nigel Wray

(b)  Date of disclosure: 26 June 2017

(c)   Date of relevant change: 23 June 2017

(d)  Price, amount and class: 8,000,000 ordinary shares of 1p each; price not disclosed

(e)  Nature of transaction: sale of shares

(f)   Nature and extent of significant shareholder's interest: direct and indirect interests

(g)  Resultant shareholding: 1.59% (direct) and 1.59% (indirect) = 3.18% total

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			ALLIANCE PHARMA PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		NIGEL WRAY
4. Full name of shareholder(s)  (if different from 3.):iv		UBS PRIVATE BANKING NOMINEES LTD ROY NOMINEES LIMITED
5. Date of the transaction and date on which the threshold is crossed or reached: v		23 June 2017
6. Date on which issuer notified:		26 June 2017
7. Threshold(s) that is/are crossed or reached: vi, vii		3%

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares		Number of voting rights			% of  voting rights x
Direct		Direct xi		Indirect xii	Direct			Indirect
Ordinary shares GB0031030819	23,092,593			23,092,593			7,551,269		7,551,269		7,541,324	1.59%			1.59%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv					Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii			Number of voting rights instrument refers to				% of voting rights xix, xx
													Nominal			Delta
Total (A+B+C)
Number of voting rights								Percentage of voting rights
15,092,593								3.18%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees 7,551,269 held by UBS Private Banking Nominees Ltd The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited   - 7,541,324
Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A
13. Additional information:	Figures are based on a total number of voting          rights of 474,307,589
14. Contact name:	Nigel Wray
15. Contact telephone number:	020 7647 7647

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLPGUQPQUPMGQQ